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                            INTRODUCTION 
        Type 2 diabetes mellitus is associated with metabolic syndrome and 
specific microvascular complications namely diabetic retinopathy, diabetic 
nephropathy and diabetic neuropathy. Many studies had proven that persistent 
hyperglycemia and associated metabolic syndrome features like hypertension, 
dyslipidemia and obesity contribute to the development of microvascular 
complications. All these metabolic derangements exist for many years in the 
asymptomatic phase of type 2 diabetes and they predispose to development of 
complications even before clinical diagnosis. 
     India is claimed to be the diabetes capital of the world and it has a large low 
socio-economic group population affected by this disease. Chronic 
complications of diabetes cause a substantial burden for both the patient and the 
health care system. The level of awareness about the symptoms, complications 
of diabetes and the necessity for early and sustained care for the disease is 
lacking in low socio-economic group population. This target group tends to 
present late to the health care system and hence expected to have high 
prevalence of micro vascular complications compared to the general population 
with diabetes. 
     Metabolic syndrome is considered to be a precursor of type 2 diabetes. 
Metabolic syndrome usually is associated with high socio-economic group and 
western population, who consume high calories and follow sedentary lifestyle. 
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Hence it is thought to be a syndrome of plenty rather than poverty. Prevalence 
of metabolic syndrome in low socio-economic group has not been well studied. 
     There are very few studies in India about the prevalence of microvascular 
complications and metabolic syndrome in low socio-economic group population 
particularly in early stages of type 2 diabetes. There is lacuna of knowledge 
about the disease characteristics in this target group. This study aims to address 
this issue. 
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                             AIMS AND OBJECTIVES 
1. To study the prevalence of micro vascular complications in newly 
diagnosed type 2 diabetes mellitus patients of low socio-economic group. 
2. To assess the prevalence of metabolic syndrome in newly diagnosed type 
2 diabetes mellitus patients of low socio-economic group. 
3. To know the average duration of early presentation of diabetes in 
subsequent generations (generation gap of onset of diabetes) in subjects 
belonging to low socio-economic group. 
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                            REVIEW OF LITERATURE 
                                            DIABETES MELLITUS 
DEFINITION1  
     Diabetes mellitus is characterized by chronic hyperglycemia with 
disturbances of carbohydrate, fat and protein metabolism resulting from defects 
in insulin secretion, insulin action, or both. 
DIAGNOSTIC CRITERIA1 
1. Fasting plasma glucose ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no 
caloric intake for at least 8 hours*. 
                                                         (or) 
2. 2 hour post load glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The 
test should be performed as described by WHO, using a glucose load containing 
the equivalent of 75 grams anhydrous glucose dissolved in water*. 
                                                        (or)  
3. Symptoms of diabetes plus casual plasma glucose concentration ≥ 200 mg/dl 
(11.1 mmol/l). Casual is defined as any time of day without regard to time since 
last meal. The classic symptom of diabetes include polyuria,   polydipsia and 
unexplained weight loss. 
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* In the absence of unequivocal hyperglycemia, these criteria should be 
confirmed by repeat testing on a different day. 
EPIDEMIOLOGY 
       Overall the prevalence of diabetes is expected to increase worldwide by 
122% (from 135 million to 300 million people) from 1995 to 2025; 90% of 
these people will have type 2 diabetes. The developing world will suffer the 
most, with a predicted 170% increase in cases that will mainly affect the 45 to 
64 years age group; by contrast the diabetic population in developed countries 
will increase by only 40% and particularly among those aged > 65 years2. 
Indian scenario 
      According to the most recent estimates India has the largest number of 
diabetic patients in the world, estimated to be 40.9 million in the year 2007 and 
expected to increase to 69.9 million by the year 20253. Type 2 diabetes in Asian 
Indians differ from the western population in that the disease onset is at younger 
age, obesity is less common, and genetic factors appear to be more common4. 
Both thrifty genotype and thrifty phenotype hypotheses hold good for the Indian 
population. Thrifty genotype hypothesis is applicable to the Indian population as 
a whole while thrifty phenotype could be applicable for low-socio economic 
group population. 
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Thrifty Genotype v/s thrifty phenotype  
Thrifty Genotype hypothesis    
     Because food supply was neither predictable nor consistent throughout most 
of the history of Homo sapiens, it is likely that ancestral hunter-gatherers 
experienced alternating cycles of feast and famine5. It is postulated that 
evolutionary pressures in the late Paleolithic era favored the selection of   
‘thrifty genes’ for efficient intake and utilization of fuel stores6 thereby 
promoting storage of fuel for periods of impending famine. It appears that these 
thrifty genes have not changed appreciably for the past 10,000 years and 
certainly not with the explosion in the prevalence of type 2 diabetes during the 
past 40 to 100 years7.  
   
Thrifty phenotype hypothesis  
      Retrospective studies have shown that low birth weight is associated with 
insulin resistance and type 2 diabetes in adult life (especially in subjects who 
become obese),   perhaps indicating that poor fetal nutrition may influence long-
term   metabolic responses8.   Maternal protein restriction has been shown to be 
associated with many metabolic defects in adult offspring, including insulin 
resistance9. 
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 Type 2 Diabetes in Low Socio – economic group 
 Possible causes are: 
1.  Thrifty phenotype, poverty, lack of education and awareness about 
diabetes and inner-city deprivation emerge as significant risk factors.   
2. Dramatic increases in the consumption of low-cost fat and simple 
carbohydrate calories have resulted in steep increases in incidence of 
overweight and obesity even among the poorest individuals. 
3. Increase in life expectancy even among low socio-economic group is also 
important, as diabetes prevalence rises with age.  
PATHOGENESIS OF TYPE 2 DIABETES 
Genetics v/s Environmental Factors 
     Diabetes is viewed as a multi-factorial disorder with genetic factors 
conferring an increased susceptibility upon which environmental factors must 
act in order for hyperglycemia to develop. It is estimated that between 25 and 
75% of the occurrence of type 2 DM can be attributed to genetic factors10. Type 
2 DM is a polygenic disorder. The interaction between genetic and 
environmental factors varies between populations and between persons. Recent 
rise in the incidence of diabetes to pandemic proportions must be largely 
attributed to the environmental factors mainly diabetogenic life-style factors. As 
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modern lifestyles spread, the most genetically vulnerable individuals develop 
diabetes first followed progressively by the capture of those with lower 
inherited susceptibility; those with the most protective genetic make-up mainly 
remain unaffected. Thus communities and ethnic groups with different 
underlying genetic susceptibilities will develop different prevalence rates of 
diabetes in response to a similar degree of life-style change.  
Insulin Resistance v/s Beta cell failure  
     Most patients with type 2 dm exhibit two apparently different defects:   
(a) Insulin Resistance- an impairment in the ability of muscle, fat and liver to 
respond to insulin action  
 (b) Failure of beta cell to compensate for this insulin resistance by 
appropriately increasing insulin secretion11.     
     The ability of beta cells to adapt to insulin resistance by increasing insulin 
secretion depends on various genetic factors that determine the total beta cell 
mass, rates of replication and apoptosis of the cells, and the activity of the key 
biochemical components of these cells12-14. In addition, environmental factors 
can probably aggravate the genetic predisposition to beta cell failure. Even 
though the beta cell failure occurs, there is substantial secretary capacity 
maintained by remaining beta cells. Thus the plasma insulin concentration is 
high enough to prevent the massive increases in triglyceride break down and 
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ketone-body formation in type 2 diabetes. This feature differentiates Type 2 
from Type 1 diabetes. 
Natural history of type 2 diabetes              
Insulin resistance is a consistent finding in type 2 diabetes15-17 Prospective 
studies have shown that insulin resistance predates the onset of type 2 diabetes 
by 10 to 20 years and is the best clinical predictor of subsequent development of 
type 2 diabetes18,19. Type 2 diabetes is characterized by an asymptomatic phase 
between the actual onset of diabetic hyperglycemia and clinical diagnosis. This 
phase has been estimated to last at least 4-7 years. Consequently 30% of type 2 
diabetes patients remain undiagnosed20. Initially insulin resistance is 
compensated for by the adaptive capacity of the beta cells to increase insulin 
concentrations, thus preventing any serious disturbance in glucose homeostasis. 
Ultimately insulin secretion reaches a plateau, during which blood glucose 
levels rise initially into the subclinical stage of pre-diabetes. Pre-diabetes 
includes Impaired Glucose Tolerance (IGT) and Impaired Fasting Glucose 
(IFG). This process usually takes several years and IGT is considered as an 
intermediate stage in the evolution of Type 2 diabetes21. However, the 
development of frank diabetes mellitus appears to require an additional defect  
in insulin secretion22. This defect in insulin secretion called beta cell failure 
coincides with the progression from IGT to frank   diabetes23-27. 
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Clinical features 
      Type 2 diabetes has a gradual and insidious onset. Usual age of onset is over 
40 years of age but increasingly the disease is becoming more common in 
younger adults and even in children. The diagnosis is made incidentally during 
hospital visits in almost one-third of cases and almost one-half do not complain 
of obvious diabetic symptoms.  
Symptoms of diabetes 
     Classical symptoms of diabetes are polyuria, polydypsia, and weight loss. 
Other important symptoms of diabetes that help in diagnosis include fatigue, 
weakness, blurring of vision, repeated skin infections, non-healing wound, 
balanophosthitis, vulvovaginitis, pruritis vulvae, urinary tract infections, 
gingivitis, periarthritis shoulder, and neuropathic symptoms described below. 
Treatment of type 2 dm  
     Assessment of glycemic control is best done by measuring biochemical 
parameters. Indexes such as body weight, frequency of polyuria, polydipsia, 
number of hypoglycemic reactions, fatigue and sense of well-being are 
important clinical parameters but can be misleading about the overall level of 
control.  Patients with very poor control often can be identified easily by their 
symptoms; however patients whose fasting glucose levels are 140 to 180 mg/dl 
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and postprandial glucose levels are 180 to 240 mg/dl can feel quite well and 
present a false clinical picture of satisfactory diabetes control. 
Clinical goals as defined by ADA 
     In the most recent standards of glycemic control, the ADA recommends a 
HbA1c of less than 7%, a pre-prandial plasma glucose level of 90 to 130 mg/dl 
and a postprandial plasma glucose level of less than 180 mg/dl28. 
Treatment options 
     Diet, lifestyle modifications, oral anti-diabetic drugs and insulin are the 
important modalities available. Choices of medications are individualized based 
on the duration of the disease, severity of metabolic derangements, motivation 
level of the patient with regards to the glycemic goals, awareness about the 
symptoms and hypoglycemic reactions. Majority of patients respond to 
treatment with oral anti-diabetic agents initially but over a period of time the 
response decreases. Almost 60 % of type 2 diabetes patients need insulin 
testament after 7- 10 years of diabetes detection, because oral hypoglycemic 
agents become ineffective33,34. 
Prognosis     
     Life expectancy is reduced by approximately 5-10 years in middle-aged 
people as compared to the general population29-32. Life expectancy is reduced 
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even more in women, in those with microvascular complications or 
cardiovascular risk factors and in those with a long duration of diabetes or 
whom the disease presented at a younger age and in those with poor blood 
glucose or blood pressure control29. 
 
    MICROVASCULAR COMPLICATIONS IN DIABETES 
     Various systemic factors such as hyperglycemia, hypertension,  
dyslipedemia, over-activity of the sympathetic nervous system and vascular 
inflammation  affect the tissues that are prone to diabetic micro vascular 
complications. All these changes begin to develop at least 9 to 12 years before 
clinical diagnosis. 
       On a cellular level, striking similarities exist between many mechanisms 
thought to be responsible for microvascular complications. Cellular mechanisms 
responsible are (a) formation of advanced glycation end-products due to 
increased intracellular glucose concentrations, (b) oxidative stress resulting 
from activation of polyol pathway and   inhibition of pentose phosphate 
pathway (c) activation of Protein Kinase C. 
     The microvasclar complications of diabetes are diabetic neuropathy, diabetic 
retinopathy and diabetic nephropathy. 
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DIABETIC NEUROPATHY  
(a) Chronic distal sensorymotor  polyneuropathy (DSPN): 
     The most common form of Diabetic neuropathy is chronic distal 
sensorymotor  polyneuropathy (DSPN)  which is often insidious in onset and 
asymptomatic. It may be detected by chance during routine clinical examination 
and may present even with complications like painless foot ulcer. Acute sensory 
(painful) neuropathy is a distinctive variant of DSPN35-37.  
(b) Acute sensory (painful) neuropathy: Many of the symptoms of acute 
sensory and chronic sensorimotor neuropathy are similar but there are clear 
differences in the mode of onset, accompanying signs and prognosis. The 
differences between acute sensory and chronic sensorymotor neuropathy37,40,41  
is given below: 
                                              Acute sensory                     Chronic sensorimotor 
  
 
   Mode of onset                            Relatively rapid                           Gradual, insidious 
 
   Symptoms                                Severe burning pain,                    Burning pain 
                                                      aching: weight loss usual                parasthesiae, numbness;                          
                                                                                                              weight loss unusual                                 
                                   
  Symptom severity                      + + +                                        0  to  + + 
 
  Signs                                          Mild sensory in some:                Stocking and glove sensory          
                                                        motor unusual                             loss: absent ankle reflexes 
  
                                               
  Other diabetic complications         Unusual                                  Increased prevalence 
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  Electrophysiological                 May be normal or minor            Abnormalities unusual in 
    investigations                             abnormalities                              motor and sensory                                  
                                                                                                           nerves 
 
  Natural history                          Complete recovery within         Symptoms may persist 
                                                       12 months                                intermittently for years:                                 
                                                                                                        at risk of foot ulceration 
          Contrary to the belief that acute painful neuropathy is always a small fiber 
neuropathy, a recent review based on sural nerve biopsies concluded that 
painful neuropathy is not restricted to selective involvement of small or large 
fibers38-40. It may be related to neural ischemia precipitated by sudden flux in 
blood glucose levels. 
  Apart from the above differentiation, based on the type of fibers involved 
neuropathy can be classified as described below into small and large fiber 
neuropathy.  
(i) Small fibre neuropathy  
     Symptoms: (a) positive symptoms42 such as burning pain, pins and needles 
sensation, aching pain, paraesthesia, dysaesthesia – becoming worsened at 
night-time and when the patient is stressed or tired (b) negative symptoms 
include numbness.  
      Diagnosis: by 1 gm Semmes-Weinstein monofilament and pricking 
sensation using the Waardenberg wheel, thermal perception testing, quantitative 
autonomic function tests. Electro physiologically it is silent.  
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(ii) Large fibre neuropathy  
     Symptoms: impaired vibration sensation (often the first objective evidence) 
and position sense, depressed deep tendon reflexes and delta type deep-seated 
gnawimg , dull or even crushing or cramp-like pain, sensory ataxia, wasting of 
small muscles of feet.  
     Diagnosis: Bedside examination for ankle jerk and with 128 Hz tuning fork 
is important. Biothesiometry for measuring vibration perception, 10 gm 
monofilament testing for pressure sensation, thermal perception threshold 
testing are used. Nerve conduction studies are done mainly to rule out other 
causes of neuropathy or to identify neuropathies super imposed on DSPN.  
 
Treatment of diabetic neuropathy  
     Glycemic control is of foremost importance. Maintaining stable blood 
glucose levels without fluctuations is particularly important in managing acute 
painful neuropathy. Symptomatic treatment for painful neuropathy includes 
tricyclic antidepressants, selective serotonin reuptake inhibitors, velnafaxine, 
topical capsaicin. Second line drugs include carbamazepine, gabapentin and 
lamotrigine. In patients with neuropathy utmost care should be taken to prevent 
progression to ulcer foot. 
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DIABETIC RETINOPATHY 
      Diabetic retinopathy is a highly specific vascular complication of both type 
1 and type 2 diabetes and the duration of diabetes is significant risk factor for 
the development of retinopathy43.  Hyperglycemia33,44,45, hypertension45 , 
diabetic nephropathy46, dyslipidemia47,  and pregnancy48-50,  present a significant 
risk for the development and progression of diabetic retinopathy.    Broadly 
diabetic retinopathy is classified into nonproliferative and proliferative types.  
Signs: Earliest sign is microaneurysm. Others include dot and blot hemorrhages, 
hard exudates, venous dilatation, venous beading or loop formation, Intra retinal 
microvascular abnormalities (IRMA), proliferative changes in retinal vessels, 
macular edema. 
Diagnosis: Direct ophthalmoscopy with dilated pupil can be used to pickup 
signs. However for more precise screening fundus photography is done and 
compared with colour EDTRS standard photographs. Fundus fluorescein 
angiography is done to differentiate microaneurysm from dot hemorrhages and 
to study vascular abnormalities in the retina. 
Treatment: Focal or panretinal (scatter) photocoagulation is done depending on 
the stage of the disease. Periodical follow up is very essential to know the 
progression of disease through various stages and to plan early treatment. 
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DIABETIC NEPHROPATHY 
     In the case of type 1 diabetics, nephropathy develops usually 5 years after 
diagnosis. Because of the indefinite start of the disease the natural history of 
diabetic nephropathy in type 2 diabetics is less well characterized. Characteristic 
features of diabetic nephropathy include albuminuria, unremarkable urinary 
sediment and majority having retinopathy preceding onset of nephropathy. 
Microalbuminuria is the earliest marker for diabetic nephropathy; however not 
all patients with microalbuminuria progress to overt proteinuria and renal 
failure. It is also an independent risk factor for cardio vascular disease. 
Risk factors: Hyperglycemia, hypertension, dyslipedemia, genetical factors, 
ethnicity. 
Diagnosis of microalbumiuria: Albumin/creatinine ratio, 24 hours urine 
albumin, albumin excretion rate are used. Persistent microalbumiuria on two of 
atleast three occasions within a 3 to 6 months period is considered as diabetic 
nephropathy.  
Treatment: Apart from strict glycemic control normalizing or even sub-
normalizing blood pressure is essential51,52.  Angiotensin converting enzyme 
inhibitors and Angiotensin receptor blockers are first choice drugs in controlling 
hypertension and delaying progression of renal disease. 
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Epidemiology of microvascular complications in undiagnosed and 
newly diagnosed type 2 diabetes: 
      Prevalence of undiagnosed diabetes is about 30% of all cases of diabetes 53.  
In secondary analysis of US National Health and Nutrition Examination Survey 
(NHANES) of undiagnosed diabetes patients, 24.9% were found to have 
nephropathy and 21.5% were found to have peripheral neuropathy54.  20% of 
persons of undiagnosed diabetes in the US population had retinopathy55. In 
Hoorn screening study conducted in Netherlands on newly diagnosed diabetic 
patients visiting general practice, 1.9% were found to have diabetic retinopathy, 
48.3% were found to have impaired foot sensitivity, and 26.7% were found to 
have microalbuminuria56. 
Indian Scenario 
     In the Chennai Urban Rural Epidemiological Study (CURES) conducted in 
Chennai with a subgroup consisting of newly diagnosed diabetics from general 
population, 5.1% of subjects had retinopathy57, 23.8% had microalbumiuria58 
and 3.6% had macroalbuminuria58.  
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                                 METABOLIC SYNDROME 
     Metabolic syndrome is characterized by clustering of metabolic 
abnormalities which included insulin resistance, glucose intolerance, 
huperinsulinaemia, dyslipidaemia and hypertension. This cluster occurring in 
the same individual appears to confer a substantial additional cardiovascular 
risk, over and above the sum of the risk associated with each abnormality59-61. 
Historical background 
     In the Banting lecture of 1988 Gerarld Reaven introduced the term 
‘syndrome X’ for describing Metabolic Syndrome62. In 1989 it was described 
by Kaplan as the ‘Deadly Quartet’ 63 and then as the ‘Insulin Resistance 
Syndrome’ 64,65. In 1936, Himsworth described two distinct forms of diabetes, 
insulin ‘sensitive’ and ‘insensitive’, and initiated the concept of insulin 
resistance as fundamental etiological factor in the development of type 2 
diabetes66. Twenty years later, Vague observed that central distribution of 
adiposity was a risk factor for diabetes and atherosclerosis, accounting for the 
higher prevalence of these conditions in males66. In 1966 Welborn et al 
demonstrated that patients with essential hypertension had elevated insulin 
levels, highlighting the link between dysfunctional insulin action and risk of 
cardiovascular disease. In 1970s, Reaven’s group showed that type 2 diabetes is 
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characterized by a reduction in insulin’s ability to stimulate whole-body glucose 
uptake (insulin resistance) 63. 
Epidemiology 
      Metabolic syndrome is believed to be driving the twin global epidemics of 
type 2 diabetes and cardiovascular disease. Prevalence of metabolic syndrome 
increases with age. Using the NCEP –ATP III guidelines, the estimated 
prevalence of metabolic syndrome in the United States is currently greater than 
20% among all adults older than 20 years of age, and greater than 40% among 
the population older than 50 years.  It is estimated that around a quarter of the 
world’s adult population have metabolic syndrome69 and they are twice as likely 
to die from and three times as likely to have a heart attack or stroke compared 
with people without the syndrome59.  
Role of various components of Metabolic Syndrome: 
       Among the components of metabolic syndrome insulin resistance and 
central obesity are considered important risk factors. Genetics, physical 
inactivity, ageing, proinflammatory state and hormonal changes may also have a 
causal effect, but the role of these may vary depending on ethnic group70,71. 
1. Insulin resistance and atherogenic lipid profile – Strongly associated with 
irregularities in both glucose and lipid metabolism, insulin resistance is the 
underlying feature of both metabolic syndrome and type 2 diabetes. Insulin 
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resistance causes decreased activity of lipoprotein lipase, and enhanced 
paracrine actions of cytokines in the adipose cells of abdomen result in 
increased delivery of free fatty acids to the liver via the portal circulation. This 
causes an increased production of VLDL and apolipoprotein B which in turn 
results in increased exchange of cholesteryl esters from HDL/LDL to VLDL 
along with triglyceride from VLDL TO HDL/LDL72-75. This accumulated 
triglyceride in LDL and HDL cause an increase in small dense LDL levels 
which in turn causes damage to vascular endothelial cells via generation of 
oxygen free radicals. 
2. Central obesity and physical inactivity- Obesity contributes to 
hypertension, high serum cholesterol, low HDL-c and hyperglycaemia, and is 
independently associated with higher CVD risk76-78. The mechanism by which 
excessive body fat causes insulin resistance and impairs glucose metabolism is 
not clearly defined but fat stores (particularly visceral adipose tissue) are an 
important cause of increased FFA and TGL in the skeletal muscle, which 
impairs insulin secretion, raising blood glucose levels and the likelihood of 
developing diabetes. Excess adipose tissue (particularly the visceral fat tissue in 
the abdomen) also releases inflammatory cytokines that increase insulin 
resistance in the body’s skeletal muscles. Furthermore, central obesity is also 
associated with a decreased production of adiponectin, which is the adipose-
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specific, collagen-like molecule found to have antidiabetic, anti-atherosclerotic 
and anti-inflammatory functions79. 
     Lack of physical activity may be pro-atherogenic independent of the 
associated weight gain. Aerobic exercise causes significant improvement in 
endothelial function80. 
3. Hypertension and insulin resistance –Whether hyperinsulinemia is a cause, 
a consequence or an epiphenomenon in hypertension remains controversial.  But 
elevation in serum insulin concentrations in patients with essential hypertension 
had been demonstrated by various cross-sectional epidemiological studies81-83.   
Role of Metabolic syndrome in Type 2 diabetes and its complications 
     People with metabolic syndrome have a fivefold greater risk of developing 
type 2 diabetes84. Type 2 diabetes in reality is a descriptive term and a 
manifestation of a much broader underlying disorder85 namely metabolic 
syndrome. Reaven demonstrated that subjects with IGT or established diabetes 
had similar degrees of insulin resistance62. Insulin resistance has more of an 
impact on macrovascular function while hyperglycemia is more closely 
associated with microvascular abnormalities, although there is a clear overlap. 
 
Role of Metabolic syndrome in cardiovascular disease (CVD)  
 23
The risk of coronary artery disease is greatly increased not only in type 2 
diabetes but also in IGT.  Cardiovascular disease (CVD) is responsible for up to 
80 percent of deaths in diabetics86,87. An increase in TGL, in addition to high 
LDL levels, significantly increases the risk for CVD while low HDL is 
considered to be a particularly key risk factor for CVD in both non-diabetic and 
diabetic individuals, as confirmed in epidemiological studies88 and in the Lipid 
Research Clinics Prevalence Study89, which found low HDL to be an 
independent contributor to CVD in both men and women and a stronger risk 
factor for CVD in people with diabetes compared with non diabetic 
individuals90. Significantly, low HDL and high TGL are frequently found with 
insulin resistance, with or without type 2 diabetes91.  
Treatment of Metabolic syndrome (IDF Recommendations) 
     Once a diagnosis of the metabolic syndrome is made, the future 
management of the condition should be aggressive and uncompromising in its 
aim to reduce the risk of CVD and type 2 diabetes. Patients should undergo a 
full cardiovascular risk assessment (including smoking status) in conjunction 
with the following: 
 
• Primary intervention 
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     The primary management for the metabolic syndrome is healthy lifestyle 
promotion. This includes  moderate calorie restriction (to achieve a 5–10 per 
cent loss of body weight in the first year),  moderate increase in physical 
activity, change in dietary composition. Studies have shown the marked clinical 
benefits associated with a small weight loss in terms of preventing (or at least 
delaying by several years) the conversion to type 2 diabetes among high-risk 
individuals with glucose intolerance who were, generally, obese92,93. 
• Secondary intervention 
     In people for whom lifestyle change is not enough and who are considered to 
be at high risk for CVD, drug therapy may be required to treat the metabolic 
syndrome. While there is a definite need for a treatment that can modulate the 
underlying mechanisms of the metabolic syndrome as a whole and thereby 
reduce the impact of all the risk factors and the long term metabolic and 
cardiovascular consequences, these mechanisms are currently unknown and 
specific pharmacological agents are therefore not yet available. Therefore it is 
currently necessary to treat the individual components of the syndrome, so that a 
reduction in the individual risk associated with each one will reduce the overall 
impact on CVD and diabetes risk. 
 
 
 
IDF recommended treatment of the individual components of the 
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Metabolic syndrome:  
(a) Atherogenic dyslipidaemia 
Primary aims for therapy: Lower TGL (as well as lowering Apo B and non-
HDL cholesterol), raise HDL-c levels, and reduce LDL-c levels (elevated levels 
represent a high risk in the metabolic syndrome) 
Options: Fibrates or statins are mainly used. Fibrates in combination with 
statins can be used but may be complicated by side effects 
(b) Elevated blood pressure 
      Categorical hypertension (BP ≥ 140 / ≥ 90 mm Hg) should be treated 
according to the JNC 7 recommendations. In patients with established diabetes, 
antihypertensive therapy should be introduced at BP ≥ 130 / ≥ 80 mm Hg94. 
(c)  Insulin resistance and hyperglycaemia 
There is growing interest in the possibility that drugs such as metformin and 
thiozolidinediones that reduce insulin resistance will delay the onset of type 2 
diabetes and will reduce CVD risk when metabolic syndrome is present95-97. 
Similarly, other studies have shown that both acarbose and orlistat can be used 
to delay the development of type 2 diabetes in patients with IGT98,99. In 
addition, emerging therapies such as incretin mimetics, dipeptidyl peptidase IV 
inhibitors, protein tyrosine phosphatase 1B inhibitors, and the endocannabinoid 
receptor blocking agents offer potential as future therapies for the metabolic 
syndrome. 
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                        MATERIALS AND METHODS 
 
Setting 
      Outpatient sections of the Department of Diabetology and the Institute of 
Internal medicine, Madras Medical College and Government General Hospital, 
Chennai – 3. 
Collaborating Departments 
     The Institute of Internal Medicine and the Department of  Diabetology, 
Madras Medical College and Government General Hospital, Chennai – 3. 
Study Design 
    Single centre, cross-sectional and analytical study. 
Period of Study 
     The work was carried out from March,2008 to September,2008, continuously 
over a period of seven months. 
Ethical Committee Approval  
     Ethical committee approval obtained from the Institutional Ethical 
committee. 
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Inclusion Criteria 
     Newly diagnosed type 2 diabetic adult patients greater than 20 years of age 
belonging to low socio-economic group (as per modified Kuppuswamy scale100) 
who gave voluntary consent were included. 
Exclusion Criteria 
• Type 1 diabetes            
• Pregnancy 
• Patients on steroid therapy  
• Patients on Angiotensin Converting Enzyme(ACE) inhibitors  
• Patients on Angiotensin Receptor Blockers(ARB) 
• Patients with urinary tract infections, fever, severely ill patients 
• Alcoholics  
• Smokers 
Sample Size 
     103 newly diagnosed type 2 diabetic patients. 
Consent 
     An informed consent was obtained from participants. 
 
Selection of study subjects 
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     Newly diagnosed type 2 diabetics were recruited randomly from the 
outpatient sections of the Department of Diabetology and Institute of Internal 
Medicine, Madras Medical College and Government General Hospital.  All 
patients recruited belong to the low socio-economic group as per the Modified 
Kuppuswamy Scale criteria100. Initially 148 subjects were recruited, of which 45 
were excluded (Impaired Glucose Tolerance-17, Impaired Fasting Glucose-8,   
patients on ACE inhibitors and ARB therapy - 4, chronic steroid therapy – 2, 
urinary tract infection - 5, alcoholics - 3, smokers -6)  
Details of study subjects 
     Their ages ranged from 25 to 72 years. All study subjects were interviewed 
during their first visit of the study and their medical history was obtained using 
a proforma. Details of the history included age, education, occupation, monthly 
income, family history of diabetes (if family history is present in consequent 
generations, then the difference in age of diagnosis – “Generation gap” of 
diagnosis of DM), symptoms of diabetes and its complications, and reason for 
attending the out-patient department. Laboratory data collected include fasting 
plasma glucose, 2 hours post 75 grams plasma glucose(OGTT), fasting lipid 
profile –   (total cholesterol, HDL,TGL), urine protein-creatinine ratio ( if 
elevated, then urine culture and sensitivity and 24 hours urine protein were 
done). Anthropometric measurements including height, weight, waist 
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circumference and blood pressure measurements were recorded. Assessments of 
microvascular complications and presence of metabolic syndrome were done. 
METHODOLOGY 
Anthropometric measurements 
     Height was measured with a tape to the nearest one centimeter. Subjects 
were requested to stand upright without shoes with their back against the wall, 
heels together and eyes directed forward. 
     Weight was measured with weighing machine using spring balance that was 
kept on firm horizontal surface. The scale was checked every day and 
calibration was done with known weights. Care was taken that the subjects wear 
light clothing and weight was recorded to the nearest 0.5 kg. 
     Waist circumference was measured using a non-stretchable plastic measure 
tape. The participants were asked to stand erect in a relaxed position with both 
feet together and one layer of clothing was accepted. At the end of expiration 
waist circumference was measured at the midpoint of lowermost border of 
twelfth rib and uppermost point of the iliac crest. 
Body Mass Index (BMI) was calculated using the formula:  
       BMI = weight (Kg) / height (m2). 
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Blood pressure (BP) measurement 
     It was done by using the sphygmomanometer (Diamond Deluxe 
sphygmomanometer). BP was recorded after making the patient to rest in the 
sitting position for ten minutes. Average of two readings taken five minutes 
apart was taken into consideration.  
Biochemical Tests 
     After a period of 8 to 12 hours fasting venous blood was drawn in the 
morning hours from the subjects visiting the out patient sections. Plasma 
glucose was measured by enzymatic (glucose oxidase – peroxidase) calorimetric 
method using semi auto- analyzer – ERBA CHEM -7. Lipid profile was 
measured by fully automated clinical chemistry analyzer - ERBA XL - 300. 
Total cholesterol and triglycerides were measured enzymatically. High density 
lipoprotein cholesterol was measured by immunoinhibition method. Urine 
protein measured by sulphosalicylic acid method. Urine creatinine was 
measured by picrate method. 
Diabetic Neuropathy 
(a) Symptomatic Neuropathy:    
      1. Positive symptoms (as compiled by consensus committee that examined 
end points for painful neuropathy101)  – Painful sensations like burning, 
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prickling, tingling, squeezing, constricting, hurting, freezing, throbbing, 
allodynia, hyperalgesia were considered. 
     2. Negative symptoms – hypoesthesia, total loss of sensation. 
(b) Quantitative Sensory Testing    
     Diabetic neuropathy was tested objectively by Bio-thesiometry. It was used 
for measuring vibration perception threshold (VPT). Patients having VPT of   < 
10 were considered as normal, 11 – 15 were considered as having mild, 16 – 20 
as having moderate,  > 20 as having severe neuropathy.  
 
Diabetic Retinopathy  
     Patients were evaluated for retinopathy at the Department of Diabetology, 
Government General Hospital and Government Ophthalmology Hospital, 
Egmore by direct ophthalmoscopy examination of dilated pupil. 
     Presence of at least one micro aneurysm was taken as the minimum criteria 
for diagnosing diabetic retinopathy. Also other features such as venous changes 
(dilatations, beading, looping), hard exudates, dot or blot hemorrhages, intra-
retinal microvascular abnormalities, proliferative changes in retinal vessels were 
considered for diagnosis. 
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Diabetic Nephropathy 
     Presence of microproteinuria (protein creatinine ratio ≥ 0.2 or 24 hours urine 
protein ≥ 150 mg) or macroproteinuria (protein creatinine ratio ≥ 3.0 or 24 
hours urine protein ≥ 500 mg) in the absence of other obvious renal diseases. 
Patients with fever, cardiac failure, renal failure, urinary tract infection (by urine 
culture and sensitivity) were excluded for the diagnosis of micro/macro 
albumunuria. 
 
DEFINITIONS 
(a) Diabetes Mellitus 
     According to the American Diabetes Association (ADA) criteria1 a fasting 
plasma glucose concentration of ≥ 126 mg/dl and a 2 hour post glucose plasma 
glucose concentration of ≥ 200 mg/dl. 
(b) Metabolic Syndrome 
     As per the International Diabetes Federation (IDF) criteria102,  
Central obesity as defined by waist circumference -for south Asians (for 
males ≥ 90 cm, for females ≥ 80 cm. If BMI >30 Kg/m2 then central obesity can 
be assumed and waist circumference need not be measured). 
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Plus any two of the following four criteria: 
1. Raised triglyceride level ≥ 150 mg/dl or specific treatment for this lipid 
abnormality. 
2. Reduced HDL cholesterol of < 40 mg/dl in males, < 50 mg/dl in females 
or specific treatment for this lipid abnormality.  
3. Raised blood pressure – systolic BP ≥ 130 mm Hg, diastolic BP ≥ 85 mm 
Hg or specific treatment for previously diagnosed hypertension.   
4. Raised fasting plasma glucose ≥ 100 mg/dl or previously diagnosed type 
2 diabetes. 
 (c) Socio-economic status scale 
     Kuppuswamy’s socioeconomic status scale is an important tool in hospital 
and community based research in India. It takes into account the education, 
occupation and total income of all the earning members of the family (family 
income per month) as the criteria for stratifying the socio-economic status.  
Initially it was proposed in 1976 103 and later modified in 1998104 and 
subsequently revised in 2007 100 after adjusting for the current inflation with a 
new base year of 2001. 
     In this study, subjects with total score   ≤ 10   are considered as belonging to 
low socio-economic group. The latest modification of Kuppuswamy’s scale 
which was followed in this study is given below: 
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Kuppuswamy’s  Socioeconomic  Status  Scale: 
 
(i) Education                                                            Score 
1. Profession or Honors                                                7 
2. Graduate or post graduate                                        6 
3. Intermediate or post high school diploma                5 
4. High school certificate                                              4 
5. Middle school certificate                                          3 
6. Primary school certificate                                         2 
7. Illiterate                                                                     1 
 
(ii) Occupation                                                         Score 
1. Profession                                                                10 
2. Semi-Profession                                                        6 
3. Clerical, Shop-owner, Farmer                                   5 
4. Skilled worker                                                           4 
5. Semi-skilled worker                                                  3 
6. Unskilled worker                                                       2  
7. Unemployed                                                              1 
 
(iii) Family income per month (Rupees)               Score 
 1.   Above 19575                                                        12 
2.   9788-19574                                                           10 
3.   7323- 9787                                                              6 
4.   4894- 7322                                                              4 
5.   2936-4893                                                               3 
6.   980-2935                                                                 2 
7.   Below 979                                                               1 
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Total Score                                      Socioeconomic class 
 
26-29                                                Upper  
16-25                                                Upper Middle  
11-15                                                Middle, Lower middle  
5-10                                                  Lower, Upper lower 
<5                                                     Lower  
 
(c) Family History 
     Family history of diabetes was considered as positive if at least one among 
the parents or the siblings or the off springs had diabetes. If family history is 
present in subsequent generations, then the difference in age of diagnosis – i.e, 
“Generation gap” of diagnosis of DM was noted. 
(d) Physical Activity 
     Activity level was divided into sedentary and active based on a physical 
activity questionnaire comprising of job related activities and specific questions 
on exercise and leisure time activities. Housewives, retired persons, office-
workers, watchmen, shopkeepers were classified as leading sedentary lifestyle 
after getting their history of daily activities including exercise and leisurely 
activities. Daily laborers including farm laborers, construction workers, hotel 
workers, and plumbers, carpenters, laundry workers, sales men and women 
were considered as having active lifestyle.  
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Statistical Analysis  
       For comparing discrete variables (sex, metabolic syndrome, microvascular 
complications) with continuous variables (age, biochemical parameters, 
anthropometric measurements and blood pressure measurements) Student ‘t’ 
test was used. For comparing between discrete variables ‘Chi-Squared test’ was 
used. Multiple logistical regression analysis was done using sex, metabolic 
syndrome and microvascular complications as dependent variable and 
biochemical parameters, anthropometric measurements, and blood pressure 
measurements as independent variables. Data was analyzed by SPSS statistical 
software and P value of < 0.05 was considered significant and P value of < 0.01 
as more significant. Continuous variables were reported as mean ± standard 
deviation. 
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    RESULTS 
     There were 103 participants in the study group. Their characteristics are 
provided below in Table 1. 
                              Table 1:  Characteristics of study group 
     
 
Characteristics Median Mean ± SD 
Age (years) 48 48 ± 10.0 
Fasting Plasma glucose(mg/dl) 160.2 174.6 ± 46.8 
2 hrs OGTT (mg/dl) 250.2 255.6 ± 75.6 
Total cholesterol (mg/dl) 202 204.7 ± 41.9 
Triglycerides (mg/dl) 191 218 ± 83.4 
HDL (mg/dl) 44 44 ± 5.3 
Systolic BP ( mm Hg) 114 118 ± 18 
Diastolic BP (mm Hg) 80 78 ± 8 
Waist circumference  (cm) 91 90.6 ± 8.7 
Body Mass Index(Kg/m2) 26 25.9 ± 4.5 
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     Study group ages ranged from 25 to 72 years with a mean of 48 ± 10 and a 
median of 48 years. Mean values of biochemical parameters were: fasting 
plasma glucose - 174.6 ± 46.8 mg/dl, 2 hours OGTT - 255.6 ± 75.6 mg/dl, total 
cholesterol – 204.7 ± 41.9 mg/dl, triglycerides - 218 ± 83.4 mg/dl and HDL – 
44±5.3 mg/dl. Mean values of other parameters include: systolic BP 118 ± 18 
mm Hg, diastolic BP 78 ± 8 mm Hg, waist circumference 90.6 ± 8.7 cm and 
body mass index 25.9 ± 4.5 Kg/m2. 
     Among the study group there were 48 males and 55 females comprising 
46.6% and 53.4% respectively. The details are given in table 2. 
                      Table 2:  Sex wise distribution of the study group 
Sex Number(103) Percentage 
Male 48 46.6 
Female 55 53.4 
 
     Age group wise distribution of the males and females belonging to the study 
group is given in table 3 and figure 1. Majority of the subjects belonged to age 
group 41 to 50 years which was followed by age groups 51 to 60 years and then 
by 31 to 40 years. 
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                   Table 3: Age group wise distribution of study group 
Age (years) Male Female Total 
number (103) 
Percentage 
21-30 3 2 5 4.8 
31-40 9 13 22 21.3 
41-50 16 22 38 36.8 
51-60 13 15 28 27.1 
>60 7 3 10 9.7 
 
     Prevalence of microvascular complications in the study group is mentioned 
in Table 4. Symptomatic neuropathy was present in 57.3% of subjects, of which 
93.2% presented with positive painful symptoms and 6.7% presented with 
negative symptoms. Objective neuropathy (including asymptomatic neuropathy) 
was present in 39.8%, of which 68.3% have mild neuropathy and 31.7% have 
moderate neuropathy. None had severe neuropathy on objective testing. 
Asymptomatic neuropathy as detected by objective testing was present in 10.7% 
of   total subjects.  
     Prevalence of retinopathy among the study subjects was 4.9%. Nephropathy 
as defined by the presence of micro or macro proteinuria was present in 18.4% 
of study subjects.  
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                 Table 4:  Microvascular Complications in study subjects 
 
  Age group wise break up of microvascular complications are given in table 5. 
Both symptomatic and objective neuropathies have an increasing trend with age 
while retinopathy and nephropathy does not have a similar relationship.      
     Metabolic syndrome prevalence among the study group subjects are 
provided in table 6. Metabolic syndrome was present in 76.6% subjects, of 
which majority were females. Sex-wise distribution of metabolic syndrome is 
given in figure 2.  Among females 87.3% had metabolic syndrome compared to 
64.6% among males. This sex based increase in metabolic syndrome is 
statistically significant (P < 0.01). 
 
Characteristics Number 
(103) 
Percentage 
Symptomatic Neuropathy 59 57.3 
Asymptomatic Neuropathy 11 10.7 
Objective Neuropathy 41 39.8 
Retinopathy 5 4.9 
Nephropathy 19 18.4 
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        Table 5: Age group wise prevalence of microvascular complications 
Symptomatic 
Neuropathy 
Objective 
Neuropathy 
Retinopathy Nephropathy 
Age group 
Number 
(59) % 
Number
(41) % 
Number
(5) % 
Number
(19) % 
21-30 2 3.4 0 0 0 0 0 0 
31-40 16 27.1 7 17 1 20 5 26.3 
41-50 16 27.1 10 24.3 0 0 6 31.6 
51-60 21 35.6 15 36.6 3 60 5 26.3 
>60 4 6.8 9 21.2 1 20 3 15.8 
 
                          Table 6: Prevalence of Metabolic syndrome 
Sex Total 
subjects 
Subjects with  
Metabolic syndrome 
Percentage 
Male 48 31 64.6* 
Female 55 48 87.3* 
Total 103 79                   76.6 
*Significant (P < 0.01)  
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     Prevalence of surrogate markers of insulin resistance which have a major 
role in the development of metabolic syndrome is given in table 7.      
     Among the study subjects, the overall average waist circumference was 90.6 
± 8.7 with males and females having an almost equal average waist 
circumference of 90.7 ± 8.4 and 90.5 ± 9.0 respectively.  The body mass index 
(BMI) average was 25.9 ± 4.6, with males having an average of 24.9 ± 3.5 and 
females having an average of 26.9 ± 5.1. 
     Prevalence of overall abnormal waist circumference and BMI was 76.7% 
and 84.5% respectively. Among the males 62.5% had increased waist 
circumference and 79.1% had high BMI. Among the females 89.1% had 
increased waist circumference and 89% had high BMI. 
     Percentage of subjects having high TGL was 84.4% overall, with 85.4% in 
males and 83.6% in females. Total subjects having low HDL was 58.2%, with 
41.7% in males and 72.7% in females. 
     Characteristics of the subjects who had metabolic syndrome are given in 
table 8 below. Among the subjects who had metabolic syndrome, there was 
38% prevalence in the age group of 41-50 years followed by 29% prevalence in 
the age group of 51-60 years. Symptomatic neuropathy was present in 63% and 
objective neuropathy was present in 35% subjects. Also retinopathy was present 
in 5% and nephropathy in 15% of subjects. Among the subjects with metabolic 
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syndrome, family history of diabetes was present in 57%, sedentary lifestyle in 
60% and active lifestyle in the remaining 41%. 
   Table  7: Prevalence of measures of obesity and surrogate markers of  
                    metabolic syndrome 
 
Variables Overall Males Females 
Average of measures of obesity
             (Mean ± SD) 
 
   Waist circumference (cm) 90.6±8.7 90.7±8.4 90.5±9.0 
   Body mass index (Kg/m2) 25.9±4.6 24.9±3.5 26.9±5.1 
Prevalence of measures of 
obesity (%) 
 
   Waist circumference  
          (M ≥ 90 cm, F ≥ 80 cm) 
76.7 62.5 89.1 
   Body Mass Index ( ≥ 23) 84.5 79.1 89.0 
Surrogate markers of Insulin 
Resistance (%) 
 
   High Blood Pressure (mm Hg) 
          (BP ≥130/85) 
19.4 16.6 21.8 
   Hyper triglyceridemia 
       (TGL  ≥ 150 mg/dl) 
84.4 85.4 83.6 
   Low levels of HDL  
         (M < 40 mg/dl, F < 50 mg/dl) 
58.2 41.7 72.7 
Prevalence of Metabolic 
syndrome by IDF criteria (%) 
76.6 64.6 87.3 
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        Table 8: Characteristics of Metabolic syndrome positive study subjects 
Metabolic Syndrome positive 
subjects (n=79) 
Number Percentage 
Age Group (years)   
      21-30 3 4 
      31-40 18 23 
      41-50 30 38 
      51-60 23 29 
      >60 5 6 
Complications of Diabetes   
     Symptomatic Neuropathy 50 63 
     Objective Neuropathy 28 35 
     Retinopathy 4 5 
     Nephropathy 12 15 
Family History of diabetes 45 57 
Sedentary lifestyle 47 60 
Active lifestyle 32 41 
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         The association of metabolic syndrome with age, sex, symptomatic 
neuropathy, objective neuropathy, retinopathy, nephropathy, fasting glucose, 
2hours OGTT, TGL, HDL, systolic and diastolic blood pressure, waist 
circumference, body mass index was statistically analyzed as detailed above in 
table 9. Metabolic syndrome was significantly associated with sex (P < 0.01), 
HDL (P < 0.05), diastolic BP (P < 0.05), waist circumference (P < 0.01) and 
body mass index (P < 0.01). 
      The association of other dependent variables and independent variables 
among the total study subjects were statistically analyzed. In the Chi square 
tests, significance was noted between sex and diabetic nephropathy (P < 0.05). 
Also significance was noted between different age groups and both 
symptomatic neuropathy (P < 0.05) and objective neuropathy (P < 0.01). 
     In the ‘t’ test, significance was noted between nephropathy and fasting 
plasma glucose (P < 0.05). Also significance was noted between lifestyle 
pattern and HDL (P < 0.05). 
     Multiple logistical regression analysis was also done. In this dependent 
variables like metabolic syndrome, microvascular complications, lifestyle 
pattern were compared individually with independent variables like biochemical 
parameters, waist circumference and blood pressure measurements. There was 
no statistical significance noted.  
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              Table 9: Metabolic syndrome in relation to characteristics 
Variables P  value 
MS and age 0.226NS 
MS and sex 0.007** 
MS and symptomatic neuropathy 0.195NS 
MS and objective neuropathy 0.101NS 
MS and retinopathy 0.858NS 
MS and nephropathy 0.122NS 
MS and fasting glucose 0.238NS 
MS and 2 hours OGTT 0.164NS 
MS and total cholesterol 0.225NS 
MS and Triglycerides 0.383NS 
MS and HDL 0.020** 
MS and systolic BP 0.441NS 
MS and diastolic BP 0.027** 
MS and waist circumference 0.000** 
MS and body mass index 0.000** 
MS and lifestyle 0.919NS 
MS and family history 0.477NS 
 
       ** Significant                                                   NS- Not Significant 
       MS - Metabolic Syndrome                               OGTT - Oral Glucose Tolerance Test 
       HDL - High Density Lipoprotein                     BP - Blood Pressure 
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       Details of the family history of diabetes are mentioned in Table 10. Family 
history of diabetes was present in 55.3%. Among the total subjects, 34.9%  had 
family history of diabetes in either their parents or children.  20.4% of subjects 
had family history of diabetes only in their siblings. 
                 Table 10: Pattern of family history in the study group 
Family History Number (103) 
Percentage 
Family history in subsequent generation 36 34.9 
Family history in same generation  21 20.4 
Total subjects with family history 57 55.3 
Subjects without family history 46 44.7 
 
     All the subjects were asked for family history of diabetes and recorded as 
pedigree chart. The age of diagnosis of diabetes in family members was 
recorded as per their history. Of the 36 subjects with family history of diabetes 
in subsequent generation the mean duration of early presentation was 16.4 ± 
7.1 years with a minimum of 5 years and maximum of   30 years. 
     Sex wise prevalence of family history is given in table 11. Family history 
was present in 52% of males and 58% of females. 
                         Table 11: Sex-wise prevalence of family history 
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Males Females 
Family history 
Number(48) % Number % 
Present 25 52 32 58 
Absent 23 48 23 42 
      Not Significant (P > 0.05)  
     Lifestyle pattern of the study group is given in table 12. Active lifestyle was 
present in 40.7% and sedentary lifestyle in 59.2%.  
                      Table 12: Lifestyle pattern of the study group 
Lifestyle Number(103) Percentage 
Active  42 40.7 
Sedentary 61 59.2 
      
      Sex wise lifestyle pattern of the study group is given table 13. Active 
lifestyle was present in 65% of males and 20% of females. Sedentary lifestyle 
was present in 35% of males and 80% of females. 
 
                    Table 13: Sex-wise lifestyle pattern of the study group. 
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Male Female 
Life style 
Number(48) % Number(55) % 
Active 31 65 11 20 
Sedentary 17 35 44 80 
     Significant (P < 0.01) 
     The reason for attending the Diabetology or Medicine outpatient clinic was 
asked to the subjects. Among them 76.7% were referred from other 
departments of the hospital when there was a suspicion of diabetes. 23.3% of 
the total subjects presented themselves for diabetes screening, either as part 
of master health checkup programme or because of doubts about their glycemic 
status (due to the symptoms of diabetes or family members having diabetes).  
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                                          DISCUSSION 
     This is one of the very few studies specifically designed to study the disease 
characteristics in newly diagnosed diabetics. This is the first study from this 
part of India which targets exclusively low socio-economic group, who form 
the majority of the Indian population and who depend mainly on government 
health services. In this study the sample population had fairly equal 
representation between males (46.6%) and females (53.5%). 
     Various studies had been published regarding the prevalence of 
microvascular complications in diabetic population from different parts of India 
and the world involving different ethnicity. However very few studies had been 
published regarding the prevalence of microvascular complications in newly 
diagnosed type 2 diabetes as mentioned in table 14. 
     The prevalence of diabetic neuropathy varies between different studies 
depending on the methods used for diagnosis. Generally newly diagnosed 
diabetics have two types of neuropathy – (i) acute painful neuropathy which is 
related to uncontrolled hyperglycemia and sudden glucose flux and (ii) the 
classical neuropathy in diabetes - the chronic distal sensorymotor 
polyneuropathy (DSPN), which is related not only to hyperglycemia but also the 
chronic duration of the disease. Even this classical form is prevalent in newly 
diagnosed  diabetics since  the  pathology of  type 2 diabetes starts much earlier 
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Table 14: Studies on the prevalence of microvascular complications in 
NEWLY DIAGNOSED type 2 diabetes 
 
 
Prevalence of microvascular complications 
Objective 
Neuropathy Retinopathy Nephropathy Author 
Number 
of 
subjects 
Method 
used % Method used % Type of albuminuria % 
Eva M. Kohne, et al105 
  
    2964 
  
 
 
 
 
Fundus 
photography 
  (ETDRS 
Protocol) 
  37.3 
 
 
 
 
 
Mohan Rema, et al57 
 
      351 
        
 
 
 Fundus 
Photography 
   (ETDRS 
Protocol) 
   5.1 
 
  
Dowse GK, et al107       358   Fundus 
photography 
 14.8   
Annemieke MW 
Spijkerman, et al56 
 
       60 10 gram 
Monofila-
ment 
48.3 Fundus 
photography 
   1.9 Microalbuminuria  26.7 
      
Richelle J Koopman, 
et al54 
 
     132 
 
10 gram 
Monofila-
ment 
21.5  
 
 Microalbuminuria 
 
21.5 
 
Ranjit  Unnikrishnan 
I, et al58 
     353     Microalbumiuria 23.8 
Collins VR, et al106      138     Microalbuminuria 26.0 
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before clinical detection. In this study neuropathy was classified as 
symptomatic, asymptomatic and objective neuropathy.  
     The prevalence of symptomatic neuropathy in this study was 57.3% which is 
substantial. Symptomatic neuropathy includes patients with positive and 
negative symptoms. Among the symptomatic patients, majority (93.2%) had 
positive symptoms and only 6.7% had negative symptoms.  Positive symptoms 
indicate either acute painful neuropathy or chronic DSPN and distinguishing 
these two based on symptoms alone is difficult since the nature of symptoms is 
common to both. From this predominance of positive symptoms in newly 
diagnosed diabetcs it is clear that the nature of neuropathy in newly diagnosed 
diabetes is mainly due to hyperglycemia (acute or chronic) and sudden glucose 
flux, leading to alteration in nerve function. Negative symptoms which 
represent a chronic pathology due to irreversible nerve damage were seen only 
in a minority since the study group included only newly diagnosed diabetics.  
     Objective neuropathy as detected by quantitative sensory testing 
(biothesiometry in this study) was detected in 39.8% of subjects. The Hoorn 
Screening study56 done in newly diagnosed diabetics coming to general 
practitioners by Annemieke et al in Netherlands showed a prevalence of diabetic 
neuropathy as 48.3% by 10 gram monofilament testing. Another study done in 
United States using secondary analysis of the data from the National Health and 
Nutrition Examination Survey (NHANES) by Richelle J Koopman, et al, 
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showed a prevalence of diabetic neuropathy as 21.5% by 10 gram monofilament 
testing. Both these studies used 10 gram monofilament for detecting diabetic 
neuropathy, which though easy to use in clinical practice and sensitive, is less 
accurate for quantitative assessment of the severity of neuropathy when 
compared to biothesiometry used in this study.   
    The difference between prevalence of symptomatic neuropathy (57.3%) and 
objective neuropathy (39.8%) in this study is due to the fact that in early stages 
of small fiber neuropathy there will not be any objective signs even though 
positive symptoms are common.  The presence of objective neuropathy at the 
time of diagnosis itself indicates that substantial proportion of patients was 
affected by chronic DSPN since acute painful neuropathy does not generally 
produce objective signs. This also emphasizes the ADA recommendation that 
all type 2 diabetic patients should be screened for microvascular complications 
at the time of diagnosis itself. Another inference is that substantial damage 
occurs to the peripheral nerves even at the time of clinical diagnosis since the 
asymptomatic phase of diabetes could be prolonged in this target population. 
     Asymptomatic neuropathy which includes subjects with no symptoms but 
showing abnormality in quantitative sensory testing was present in 10.7% of 
subjects. These asymptomatic patients also form part of the group with 
objective neuropathy.  
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     Detection of objective neuropathy, more particularly asymptomatic 
neuropathy is very important since these groups are prone to develop severe 
neuropathy and present late to the health facility and hence the dangerous 
complication of developing diabetic foot ulcer leading to amputation. Another 
importance of this data is that the study group involved only low socioeconomic 
group who are prone to walk barefoot and at very high risk for diabetic foot 
ulcer. This also emphasizes the need to educate the patients regarding the perils 
of diabetic neuropathy and the importance of proper foot care. 
     The prevalence of diabetic retinopathy in the present study was 4.9%.  
Compared to a relatively older study105 with a large sample, done in United 
Kingdom as part of the UKPDS study in newly diagnosed diabetics (which 
showed a very high prevalence of 37.3%), almost all studies56,57,107 in the past 
12 years showed a prevalence of retinopathy in the range between 1.9% and 
15%. In many multiethnic studies107,108 the prevalence of retinopathy in Asian 
Indians was comparatively low when compared to other ethnic groups. In the 
present study, the prevalence of retinopathy was 4.9% in low socioeconomic 
group and it was in line with the prevalence in CURES eye study57 done in the 
same geographical area but in the general population without any socio-
economic stratification. 
      Majority of the patients in the present study had mild form of 
nonproliferative diabetic retinopathy. None of the cases had severe 
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nonproliferative diabetic retinopathy or proliferative diabetic retinopathy. 80% 
of subjects with retinopathy had associated nephropathy. This association is 
well known and demonstrated in many other studies in diabetes. 
     The prevalence of diabetic nephropathy in the study group was 18.4%. All 
the subjects with diabetic nephropathy had microproteinuria. Only one subject 
had macroproteinuria but not included in the study, since the subject had 
preexisting Henoch-schonlein purpura and was on chronic steroid therapy. 
There was no major influence of high blood pressure on the development of 
microproteinuria in this study, since only 15.8% with microproteinuria had high 
blood pressure with systolic BP ≥130/85mm Hg.  
    The prevalence of microalbuminuria among newly diagnosed diabetics in 
different ethnic studies54,56,106 range between 20% and 30%. In the CURES 
study58 done in the same geographical area the prevalence of microalbuminuria 
was 23.8%. Present study which used microproteinuria as the method for 
diagnosis of diabetic nephropathy had shown a prevalence of 18.4%. 
     Metabolic syndrome (MS) which is considered as an important forerunner 
for both diabetes and cardiovascular disease (CVD) was analyzed in detail in 
this study among low socioeconomic group subjects. The prevalence of MS in 
this study was 76.6% among low socioeconomic group. This finding is 
important in the context that MS is considered a disorder related to high calorie 
intake and sedentary activity. The target population in this study was generally 
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expected to involve in jobs which require substantially high physical activity. 
But this study showed that sedentary lifestyle among low socioeconomic group 
was present in 60% of the MS positive subjects. The high prevalence of MS 
along with sedentary lifestyle in this study proves the fact that even the low 
socioeconomic group population are at increased risk for both diabetes and 
CVD.  
     Comparative studies on the prevalence of metabolic syndrome in newly 
diagnosed diabetics cannot be found in the literature. So studies done in general 
population and diabetic population from Asian Indians are compared with the 
study group. Table 15 gives details about comparative studies. 
      The recent studies done in Delhi and Jaipur in general population by Wasir 
JS, et al109 where a subgroup included the diabetics showed a prevalence of MS 
as 73.5% by IDF criteria. Similarly another study done by Surana SP, et al110 in 
Mumbai in diabetics showed a prevalence of MS as 77.2%. Both these recent 
studies  published in 2008 along with other studies112-115 though used different 
criteria for diagnosis, showed almost similar prevalence of MS. The present 
study also had a similar prevalence of MS (76.6%) in newly diagnosed diabetics 
of low socioeconomic group.  
     Another important finding of the present study was high prevalence of MS in 
females (87.3%) than males (64.6%) which was statistically very significant.  
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              Table 15: Studies on the prevalence of metabolic syndrome 
  
 
 
 
Total Subjects Male Female  
Author/target 
poulation Number 
% of 
MS 
Number
% of 
MS 
Number
% of 
MS 
Criteria 
used 
Ethnicity 
(Geographical 
Area) 
Wasir JS,Misra 
A, et al109 
(Sub group 
with Diabetes) 
117 
 
73.5 
 
54 
 
74.1 
 
63 
 
73 
 
IDF 
 
 
North India 
(New Delhi & 
Jaipur) 
 
Surana SP, 
 et al110 
(Diabetics) 
5088 77.2 2908 69.33 2180 87.7 ATP III 
 
West India 
(Mumbai) 
Ramachandran 
A, et al111 
(General 
population) 
475 41.1  46.5  36.4 ATP III 
 
South India 
(Chennai) 
Imam SK et al112 
(Diabetics) 
233 68.1 116 49.1 117 87.0 IDF 
 
Pakistan(Karachi)
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This trend of high prevalence of MS in diabetic females was also shown by a 
very large study by Surana SP, et al110 and many other studies. The present 
study also confirmed the same in newly diagnosed diabetics of low 
socioeconomic group. 
     MS was present in substantial number in all the age groups between 31 to 60 
years and it was low in the age groups of 21- 30 years and > 60 years. Both 
these age groups had less number of study subjects compared to the other age 
groups. The reason for the low prevalence in 21 – 30 years age group could be 
they are considered to be more active and less obese. But the low prevalence in 
the >60 years age group could be due to the small size of the sample subjects in 
that group. 
     The prevalence of microvascular complications, family history and sedentary 
lifestyle in metabolic syndrome positive subjects was almost similar to the trend 
seen in the study group in total, which was discussed earlier.  
     The association of MS with age, sex, microvascular complications, 
biochemical parameters, anthropometric measurements, lifestyle and family 
history was statistically analyzed. There was significant association with sex, 
HDL, diastolic BP and BMI. The association with waist circumference could be 
due to the selection bias since only subjects with high waist circumference 
(obligatory criteria) were considered for defining MS (IDF Criteria). 
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Table 16: Studies on the prevalence of the measures of - Obesity and 
Metabolic Syndrome 
Author / diabetic 
status 
of the study group 
 
Waist 
circumference 
(M ≥ 90cm, F 
≥ 80cm) 
% 
BMI 
( > 
23Kg/m2)
% 
High 
TGL 
(≥150 
mg/dl) 
% 
Low 
HDL(mg/dl) 
(M < 40, F < 
50) 
% 
High 
BP 
≥ 
130/85 
% 
Geographical 
Area 
 
Wasir JS, Misra A, et 
al109 
(General population) 
sample size – 2050 
Overall  
Male  
Female                          
        
 
 
 
44.5 
39.3 
48.4 
 
 
 
45.3 
47.0 
44.0 
 
 
 
26.97 
28.9 
25.5 
 
 
 
65.21 
43.8 
81.8 
 
 
 
36.9 
29.1 
42.8 
 
 
 
 
 
North Indians 
(New Delhi & 
Jaipur) 
 
Surana SP, et al110 
(Diabetics-sample 
size -5088) 
Overall 
Male 
Female 
 
 
 
46.0 
25.7 
73.2 
 
 
Not done 
 
 
 
 
57.8 
58.3 
57.2 
 
 
 
52.2 
43.0 
64.5 
 
 
 
73.3 
75.1 
71.0 
 
 
 
 
Western India 
(Mumbai) 
 
Mohan V, et al 113 
(Sub group with 
Newly diagnosed 
diabetics) 
Sample size - 61 
Overall 
 
 
 
 
50.8 
 
 
34.4 
 
 
52.5 
 
 
41.0 
 
 
47.5 
 
 
South India 
(Chennai) 
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     Studies featuring the prevalence of measures of obesity are mentioned in 
table 16. The study by Wasir JS, et al109 was from the general population. The 
study by Surana SP, et al110 was from the diabetic population and study by 
Mohan V, et al113 was from a subgroup with newly diagnosed diabetics. 
     Among the total subjects who participated in the study the prevalence of the 
measures of obesity such as high waist circumference (76.7%), high BMI 
(84.5%), high TGL (84.4%) and low HDL (58.2%) were very high in the newly 
diagnosed low socioeconomic group subjects compared to the studies in general 
population109, diabetic population110, and newly diagnosed diabetic 
population113.      When prevalence of measures of obesity in males and females 
are assessed individually, there was a trend of high prevalence noted in both sex 
for high - waist circumference, BMI and TGL - on comparsion to other 
studies109,110,113.  Low HDL prevalence in males and females was in line with 
other studies109.110,113. 
     The prevalence of hypertension in total subjects (19.4%), males (16.6%), and 
females (21.8%) in the present study was comparatively lower to other 
studies109,110,113. The reason for this difference could be that present study was in 
newly diagnosed diabetics and these subjects may develop hypertension as the 
duration of diabetes increases along with the worsening of risk factors for 
obesity and MS. 
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     Presence of family history in the study group was analyzed in detail. There 
was no significant difference in the prevalence of family history between males 
and females. Among a total of 55.3% subjects with positive family history, 
34.9% had history of diabetes in at least one of their parents and 20.4% had 
family history in their siblings. This data was very high when compared to a 
study with a sub group of newly diagnosed diabetics by Mohan V, et al113 in 
Chennai which had a prevalence of 19.7%.  Thus people from low 
socioeconomic group have a very high genetic risk when compared to general 
population as per the results of this study. 
     Among the 34.9% subjects who had family history of diabetes in subsequent 
generations, the generation gap for the onset of diabetes based on clinical 
diagnosis was analyzed. A mean duration of 16.4 ± 7.1 years was obtained. This 
generation gap of about one to two decades in low socioeconomic group is very 
significant in formulating the preventive strategies for diabetes.   
     Contrary to the popular view that people from low socioeconomic group are 
more active and involve in labour intense jobs, this study had a majority of 
59.2% leading a sedentary lifestyle. The sedentary lifestyle was predominant 
among females (80%) compared to males (35%) and it was statistically 
significant. 
     The awareness level of the subjects regarding diabetes was assessed from the 
data regarding the mode of referral. Only 23.3% subjects were able to present 
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themselves voluntarily for diabetes screening either because of awareness about 
symptoms of diabetes or because of family members being affected by diabetes 
or as part of Master Health Check-up programme. Majority of them (76.7%) 
were referred from other departments of the hospital. This indicates the fact that 
still three-fourths of the low socioeconomic group population is not aware of the 
importance of screening for diabetes and majority are diagnosed accidentally 
during health visits for other diseases. 
Strength of the study 
     Rigid criteria for inclusion of only newly diagnosed diabetics and diagnosis 
of diabetes based on fasting plasma glucose and 2 hours OGTT, studying a wide 
array of disease characteristics in a single study with reference to a particular 
socioeconomic class, and comparability of the observation with intensely 
searched published articles done in subjects from different ethnicity and 
different geographical area make this study strong. 
Limitations 
      Direct ophthalmoscopy was used in place of fundus photography for 
assessing retinopathy. Microproteinuria was measured instead of 
microalbumiuria for assessing nephropathy. But this was mainly based on 
logistical reasons. 
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 Suggestions 
     Many more large scale multi-centric studies focused on population from low 
socioeconomic class are needed to validate the findings of this study since such 
data are of immense value in formulating strategies for targeted health delivery. 
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                                                CONCLUSION 
• Prevalence of microvascular complications in newly diagnosed 
diabetics of low socioeconomic group were as follows: symptomatic 
neuropathy – 57.3%, objective neuropathy – 39.8%, retinopathy – 
4.9%, nephropathy – 18.4%. These were similar to published studies 
from general population from the same geographical area. 
• Prevalence of metabolic syndrome (76.6%) and measures of obesity in 
newly diagnosed diabetics in an unexpected manner had a similar 
trend in low socioeconomic group when compared to data from 
various studies among general population.  
• Significant association (P < 0.01) was noted between metabolic 
syndrome and sex with an increasing trend in females. Similarly 
association (P < 0.05) was found between metabolic syndrome and 
diastolic blood pressure, HDL and BMI.  
• Majority of females of low socioeconomic group had high BMI 
(89%), and had high prevalence of metabolic syndrome (87.3%) when 
compared to males of the same class. Significant association (P < 
0.01) was found between sex and lifestyle with majority of females 
leading a sedentary lifestyle. 
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• High prevalence of family history (55.3%) indicates that genetic 
component could play a major role in the pathogenesis of diabetes in 
low socioeconomic group diabetics. 
• Average generation gap for onset of diabetes based on clinical 
diagnosis was 16 years in low socioeconomic group. 
• Only 23.6% of subjects presented themselves for screening and 76.7% 
of diabetics were detected by chance during health visits to doctor for 
some other disease. 
 
 
 
 
 
 
 
 
 
 
 66
                                            SUMMARY 
     Microvascular complications and metabolic syndrome are well known facts 
related to type 2 diabetes. However there is paucity of data regarding the disease 
characteristics in low socioeconomic group. This is the reason for designing a 
cross sectional study of this type. 
      Aims and objectives were to find the prevalence of microvascular 
complications and metabolic syndrome in newly diagnosed type 2 diabetics of 
low socioeconomic group. Another objective of this study was to find out the 
generation gap of onset of diabetes in low socio economic group.   
     The data was collected from a sample of 103 newly diagnosed diabetic 
subjects belonging to low socioeconomic group. The data was analyzed 
statistically. The results of the study revealed a prevalence of symptomatic 
neuropathy (57.3%), objective neuropathy (39.8%), retinopathy (4.9%), 
nephropathy (18.4%) and metabolic syndrome (76.6%). 
     Sex, diastolic blood pressure, HDL and lifestyle were important risk factors 
associated with metabolic syndrome in this study.  
     One would expect a higher prevalence of microvascular complications in low 
socioeconomic group, because of the tendency to seek the health facility after a 
delayed period. This is due to lack of awareness about symptoms of diabetes 
and its complications and low educational level. Also another expectation is 
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lower prevalence of metabolic syndrome in low socioeconomic group since they 
consume less calorie rich diet and involve in labour intense jobs.  
     However, contrary to these expectations the prevalence of microvascular 
complications was similar in trend with the studies from general population in 
the same geographical area. Also the prevalence of metabolic syndrome was 
similar to the trend observed from studies in general population in India. Hence 
low socioeconomic group people are not different from general population as 
far as microvascular complications or metabolic syndrome is concerned. They 
should be subjected to screening for microvascular complications at the time of 
diagnosis itself. 
     Low socioeconomic group females were at more risk of diabetes and 
cardiovascular disease because of metabolic syndrome, obesity risk factors, and 
sedentary lifestyle when compared to males.  
     Future health policies of the government targeting low socioeconomic group 
population should focus more on creating awareness, not only about diabetes 
and its complications but also about promoting active lifestyle. Since the onset 
of diabetes was one to two decades earlier in subsequent generations in this 
study and majority of the study subjects were diagnosed by chance during 
health visits for other diseases, focus should be more on detecting cases earlier 
by targeted screening and initiating appropriate prevention strategies. 
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PREVALENCE OF MICROVASCULAR COMPLICATIONS AND  
 
METABOLIC SYNDROME IN NEWLY DIAGNOSED TYPE 2 DM  
 
 
 
 
Inclusion  Criteria: All newly diagnosed Type 2 Diabetics of low socioeconomic group 
Exclusion Criteria: T1 DM, Pregnancy, Therapy with -  steroids, ACE inhibitors, ARBs 
                                   Severely ill patients, Known – kidney disease, heart failure 
Name  :                                                              Age:             Sex:        
Address:                                                                         Pedigree chart 
           
  
 Education:  
Occupation: 
Income per month:                                                                   
Socio-economic status: 
 Family H/O DM: + / -    
Generation gap of onset of diabetes:                                                                                                      
H/o. GDM / HT/ CAD/Dyslipidemia/Diabetogenic drug therapy 
Smoking/Alcohol                              Diet- veg. /non-veg/ mixed 
Reason for attending Diabetology OP: 
 
- During routine evaluation : Medical OP / Surgical OP/ Specialty OP 
- Evaluation for surgical fitness / dental procedure fitness 
- Referral for other reasons – Infertility / PCOD / Obesity / Others  
      -    Referral from Master Health Check up / Self evaluation 
 
Serial No.:                  OP No.: 
Presenting Symptoms:  (for each symptom mention duration) 
- Polyuria 
- Polydypsia 
- Weight loss 
- Balanophosthitis 
- Vulvovaginitis 
- Burning micturition 
- Peri-arthritis shoulder 
- Non healing wound  
- Giddiness 
- Visual Symptoms –  
flashes/floaters/ 
refractory changes 
 
 
 
 
 
 
             Sensory symptoms 
o Burning sensation 
o Pricking, tingling 
o Squeezing, constricting 
o Throbbing, freezing 
o Loss of sensation 
o Para/Hypo aesthesia 
             Motor Symptoms 
o Tripping of toes / slipping  of 
slippers / buckling of knees  
                                            
 
 
ANTHROPOMETRIC MEASUREMENTS: 
 
Waist Circumference:               cm         
 
 Ht:                cm,            Wt:              kg,                BMI:                  
 BP:      mm/Hg 
 
 
INVESTIGATIONS: 
     
Fasting Plasma Glucose (mg/dl):      Fasting Lipid Profile (mg/dl) 
(75 grams) 2 hrs OGTT (mg/dl):                          Total Cholesterol : 
                   TGL             : 
Protein Creatinine ratio:                         HDL             : 
 
24 Hrs urine protein:                                              Urine C&S: 
  
PARAMETERS TO BE OBSERVED : 
 
1. Nephropathy:      -   Microproteinuria            -  Macroproteinuria 
 
2. Retinopathy :      -   Micro aneurysm              -  Dot/ Blot  Hemmorrahage 
                                  -   Hard exudates                 -   Soft exudates  
              -   Venous dilatations          -   Venous beading                                       
              -   Proliferative changes      -   Macular Edema 
 
3. Neuropathy :      Biothesiometry – vibration threshold :     Rt. foot  - 
                                                                                                 Lt. foot  -  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

